Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.43 |
| ▸ | METAP1 | P53582 | 3/20 | 0.41 |
| ▸ | METAP2 | P50579 | 9/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.36 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3045972 | 1.00 | SMYD3 (0.43) | SMYD3METAP1METAP2LMNABLM | |
| SCHEMBL328991 | 1.00 | SMYD3 (0.43) | SMYD3METAP1METAP2LMNABLM | |
| SCHEMBL13058644 | 1.00 | SMYD3 (0.43) | SMYD3METAP1METAP2LMNABLM | |
| SCHEMBL2331995 | 1.00 | SMYD3 (0.43) | SMYD3METAP1METAP2LMNABLM | |
| SCHEMBL13201892 | 1.00 | SMYD3 (0.43) | SMYD3METAP1METAP2LMNABLM | |
| SCHEMBL329101 | 1.00 | SMYD3 (0.43) | SMYD3METAP1METAP2LMNABLM | |
| Hydrochloric Acid SCHEMBL4205427 | 0.98 | SMYD3 (0.42) | SMYD3METAP1METAP2LMNABLM | |
| Hydrochloric Acid SCHEMBL329085 | 0.98 | SMYD3 (0.42) | SMYD3METAP1METAP2LMNABLM | |
| Hydrochloric Acid SCHEMBL329165 | 0.98 | SMYD3 (0.42) | SMYD3METAP1METAP2LMNABLM | |
| Hydrochloric Acid SCHEMBL29618100 | 0.98 | SMYD3 (0.42) | SMYD3METAP1METAP2LMNABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 282 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105085310-A | New synthesis method of telaprevir intermediate | CHONGQING HUIZHI PHARMACEUTICAL RES INST CO LTD | 2015-11-25 | — | — | CN | claimed |
| WO-2014203208-A1 | PROCESS FOR THE PREPARATION OF TELAPREVIR AND INTERMEDIATES THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2014-12-24 | — | — | WO | claimed |
| WO-2014083582-A2 | NOVEL PROCESS FOR THE PREPARATION OF (1S,3AR,6AS)-2-[(2S)-2-({(2S)-2-CYCLOHEXYL-2-[(PYRAZIN-2-YLCARBONYL)AMINO]ACETYL}AMINO)-3,3-DIMETHYLBUTANOYL]-N-[(3S)-1-(CYCLOPROPYLAMINO)-1,2-DIOXOHEXAN-3-YL]-3,3A,4,5,6,6A-HEXAHYDRO-1H-CYCLOPENTA[C] PYRROLE-1-CARBOXAMIDE AND ITS INTERMEDIATES | MSN LABORATORIES LIMITED (IN) | 2014-06-05 | — | — | WO | claimed |
| WO-2013136265-A1 | SYNTHESIS OF AN INTERMEDIATE OF AN ANTIVIRAL COMPOUND | DIPHARMA FRANCIS S.R.L. (IT) | 2013-09-19 | — | — | WO | claimed |
| US-20210338825-A1 | DEGRADERS OF HEPATITIS C VIRUS NS3/4A PROTEIN | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-11-04 | — | — | US | disclosed |
| WO-2020069125-A1 | DEGRADERS OF HEPATITIS C VIRUS NS3/4A PROTEIN | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| CN-105085310-B | New synthesis method of telaprevir intermediate | 重庆汇智药物研究院有限公司 | 2017-05-10 | — | — | CN | disclosed |
| EP-1919478-B1 | COMBINATION OF HCV PROTEASE INHIBITORS WITH A SURFACTANT | MERCK SHARP & DOHME (US) | 2016-03-23 | — | — | EP | disclosed |
| CN-105085310-A | New synthesis method of telaprevir intermediate | CHONGQING HUIZHI PHARMACEUTICAL RES INST CO LTD | 2015-11-25 | — | — | CN | disclosed |
| CN-105085310-A | New synthesis method of telaprevir intermediate | CHONGQING HUIZHI PHARMACEUTICAL RES INST CO LTD | 2015-11-25 | — | — | CN | disclosed |
| CN-104860897-A | Intermediate for preparing N-cyclopropyl-(2S, 3S)-3-amino-2-hydroxy caproamide, preparation method and applications thereof | SHANGHAI DESANO CHEMICAL PHARM | 2015-08-26 | — | — | CN | disclosed |
| EP-1906945-B1 | HCV INHIBITORS | VIROBAY INC (US) | 2015-08-05 | — | — | EP | disclosed |
| WO-2006130666-A2 | MEDICAMENTS AND METHODS COMBINING A HCV PROTEASE INHIBITOR AND AN AKR COMPETITOR | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130607-A2 | CONTROLLED-RELEASE FORMULATION USEFUL FOR TREATING DISORDERS ASSOCIATED WITH HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2005007681-A9 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | — | 2006-04-06 | — | — | WO | disclosed |
| WO-2005035525-A2 | 2-AMIDO-4-ARYLOXY-1-CARBONYLPYRROLIDINE DERIVATIVES AS INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-04-21 | — | — | WO | disclosed |
| WO-2005028502-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2005-03-31 | — | — | WO | disclosed |
| WO-2005007681-A2 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-01-27 | — | — | WO | disclosed |
| WO-2003035060-A1 | INHIBITORS OF SERINE PROTEASE, PARTICULARLY HEPATITIS C VIRUS NS3-NS4A PROTEASE, INCORPORATING A FUSED RING SYSTEM | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-05-01 | — | — | WO | disclosed |
| WO-2003006490-A1 | BRIDGED BICYCLIC SERINE PROTEASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338825-A1 | DEGRADERS OF HEPATITIS C VIRUS NS3/4A PROTEIN | HAVCR2, CUL4A, PSMC3 | SMYD3 3728/4885METAP1 385/4885METAP2 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.